Related Experiment Video

Updated: Aug 24, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Effect of Lovastatin on lipid peroxidation and total antioxidant concentrations in hemodialysis patients

Hassan Argani1, Amir Ghorbani, Nadereh Rashtchizade

  • 1Hemodialysis and Nephrology Division, Emam Hospital, Tabriz University of Medical Sciences, Tabriz, Iran. hassanargani@hotmail.com

Lipids in Health and Disease
|April 24, 2004
PubMed

Insights

Lovastatin therapy improved serum lipids and reduced lipid peroxidation in hemodialysis patients. This treatment also enhanced total antioxidant activity, crucial for managing atherosclerosis risk in this population.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Biochemistry

Background:

  • Atherosclerosis is a primary cause of mortality in end-stage renal disease (ESRD) patients, particularly those undergoing hemodialysis (HD).
  • Non-traditional risk factors, including elevated lipid peroxidation and diminished antioxidant levels, contribute to atherosclerosis pathogenesis in HD patients.

Purpose of the Study:

  • To evaluate the effect of Lovastatin on lipid peroxidation and total antioxidant levels in hyperlipidemic male HD patients.
  • To assess the changes in serum lipids, lipid oxidation, and antioxidant status over a three-month period of Lovastatin treatment.

Main Methods:

  • Forty-five stable hyperlipidemic male HD patients (age 40-60) were treated with 20 mg/day of Lovastatin for three months.
  • Serum lipid profiles (triglycerides, cholesterol, LDL-C, VLDL-C, HDL), malondialdehyde (MDA) as a marker of lipid peroxidation, and total antioxidant (TA) levels were measured at baseline, 45 days, and 90 days.

Main Results:

  • Lovastatin therapy significantly reduced serum triglycerides, cholesterol, LDL-C, VLDL-C, and MDA levels.
  • Total antioxidant (TA) levels and HDL cholesterol significantly increased after three months of Lovastatin treatment.
  • The observed improvements in HDL, VLDL, and triglycerides were more pronounced after three months compared to 45 days of therapy.

Conclusions:

  • Hemodialysis patients exhibit elevated serum lipids and increased lipid peroxidation.
  • Lovastatin treatment effectively improves both the quantity and quality of lipids and reduces oxidation in HD patients.
  • The beneficial effects of Lovastatin are likely attributed to enhanced total antioxidant activity.
Abstract

More Related Videos

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis01:30

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...